Silo Pharma Inc. (NASDAQ: SILO) has announced that the European Patent Office has issued a Rule 71(3) communication indicating its intent to grant a patent covering methods of preventing stress-induced fear and depressive-like behavior using serotonin 4 (5-HT4) receptor agonists. This development represents a significant milestone for the developmental stage biopharmaceutical company as it advances its pipeline targeting stress-related and central nervous system disorders.
The patent, which is exclusively licensed from Columbia University, is expected to strengthen Silo Pharma's intellectual property position across major European markets. This enhanced IP protection comes as the company focuses on novel formulations and drug delivery systems for both traditional therapeutics and psychedelic treatments. The company maintains a diversified approach, operating as both a biopharmaceutical and cryptocurrency treasury entity while addressing underserved medical conditions.
Silo Pharma's therapeutic focus includes stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. The company's portfolio features innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company conducts its research in collaboration with leading universities and laboratories, including the partnership with Columbia University that yielded this latest patent development.
The European patent notice arrives as Silo Pharma continues to build its position in the emerging field of psychedelic and novel psychiatric treatments. The company's latest news and updates relating to SILO are available in the company's newsroom at https://ibn.fm/SILO. This announcement was distributed through PsychedelicNewsWire, a specialized communications platform focused on psychedelics sector developments that operates within the Dynamic Brand Portfolio at IBN, which provides various corporate communications solutions including enhanced press release services and social media distribution.
For business and technology leaders monitoring the intersection of biotechnology and mental health treatment, Silo Pharma's patent progress signals both scientific validation and commercial potential in addressing stress-related disorders through novel pharmacological approaches. The European patent protection could facilitate partnerships, investment, and eventual market entry for treatments derived from this intellectual property, potentially impacting how stress-induced psychiatric conditions are treated globally. The company's website at silopharma.com provides additional information about its research programs and corporate direction as it advances these therapeutic candidates through development stages.
